Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you are putting weight on with Wegovy, or your loss has stalled and the scales have started creeping back up, you are not alone and you are not doing it wrong. Weight gain during Wegovy treatment is more common than most people expect, and almost always has a clinical explanation worth understanding. These medicines are prescription-only treatments that a prescriber manages alongside you; any significant change on the scales is worth raising with them directly. Below is a clear, honest account of the reasons it can happen.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first thing worth separating out is whether you are actually gaining body fat or whether the number on the scales reflects something else entirely. Body weight shifts considerably across a single day. Fluid retention, a high-sodium meal, constipation, or where you are in your menstrual cycle can each add 1–3 kg without any change in fat mass. Semaglutide slows gastric emptying, which means food can sit in the stomach longer than usual; if you weighed yourself shortly after a large meal, the reading will be higher than it would be first thing in the morning under consistent conditions.
The most reliable approach is to weigh yourself at the same time each day, ideally before breakfast and after using the bathroom, and to look at the trend across two to three weeks rather than any single reading. A handful of higher readings after a weekend away or a run of salty meals is not the same as a sustained upward trend. If, once you account for these variables, the gain is real and persistent, the reasons below are the ones a prescriber will want to explore with you. Our guide to what affects your weight on Wegovy covers the measurement side in more detail.
Semaglutide works partly by activating GLP-1 receptors involved in appetite and satiety, as described in the NHS semaglutide medicines information. The appetite-reducing effect is generally strongest in the weeks after a dose increase, then stabilises. For some people it can feel as though it fades sooner than expected, particularly if they have been on the same dose for several months.
A few things can blunt the effect. Chronic stress raises cortisol, which directly drives hunger and can partly counteract the satiety signals semaglutide produces. Poor sleep has a similar effect: even a week of disrupted nights shifts ghrelin and leptin in directions that increase appetite. Illness, including a stomach bug that causes vomiting, can interfere with how much of a subcutaneous dose is absorbed into circulation. None of these means the medicine has failed; they mean the circumstances around it have changed. If you feel that appetite suppression has reduced noticeably and persistently, that is worth documenting and discussing with your prescriber before drawing any conclusions.
Wegovy is titrated gradually from 0.25 mg upward. At the lower end of the schedule the dose is primarily about tolerability, not maximum therapeutic effect. If weight gain is happening at a starter or intermediate dose, it may simply be that the maintenance dose has not yet been reached. That is a normal part of the process rather than a failure, but it can be frustrating when you expected to see consistent loss from week one.
Timing matters too. Injections should be given on the same day each week. Stretching doses further apart than intended because a pen ran out or delivery was delayed means the medicine's steady-state levels in the blood drop, appetite may return, and eating patterns can shift before you consciously register the change. If you are new to Wegovy or recently restarted after a gap, some temporary weight increase before the medicine re-establishes its effect is expected.
This is a separate but closely related concern. Research consistently shows that a significant proportion of weight lost on semaglutide returns once treatment ends, because the underlying biology driving appetite and weight regulation has not changed permanently. The STEP 1 trial, published in the New England Journal of Medicine, reported that participants who stopped semaglutide regained most of their lost weight within a year. That is not a reason to avoid treatment; it is a reason to plan for what comes next.
If you have recently finished a course and are now putting weight back on, our page on weight regain after Wegovy addresses that situation specifically. If you are still on treatment and gaining weight, it is also worth reading our guide on why some people put weight on with Wegovy, which explores the specific reasons this can happen during active treatment. If you are weighing up whether Wegovy is the right option for you at all, reading about how weight loss on Wegovy typically progresses can help set realistic expectations. The honest summary: weight that is going up while you are actively on treatment, after ruling out short-term fluctuations and timing issues, needs a clinical conversation. A prescriber can look at the full picture in a way that a page like this simply cannot. Speak to our prescribers at any point if something feels off.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.